These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8002633)

  • 41. Nuclear matrix targets for anticancer agents.
    Fernandes DJ; Catapano CV
    Cancer Cells; 1991 Apr; 3(4):134-40. PubMed ID: 1652999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [DNA-topoisomerase II: Cellular targets of antineoplastic agents].
    Le Guern M
    Pathol Biol (Paris); 1987 Apr; 35(4):343-5. PubMed ID: 3035465
    [No Abstract]   [Full Text] [Related]  

  • 43. Resistance to inhibitors of DNA topoisomerases.
    Sullivan DM; Ross WE
    Cancer Treat Res; 1991; 57():57-99. PubMed ID: 1686723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
    Beck WT
    J Natl Cancer Inst; 1989 Nov; 81(22):1683-5. PubMed ID: 2553990
    [No Abstract]   [Full Text] [Related]  

  • 45. Topoisomerase I in multiple drug resistance.
    Pessina A
    Cytotechnology; 1993; 12(1-3):127-35. PubMed ID: 7764454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Multifactor resistance to various antineoplastic agents].
    Jacquemin-Sablon A
    Bull Cancer; 1989; 76(9):967-71. PubMed ID: 2559781
    [No Abstract]   [Full Text] [Related]  

  • 47. [Topoisomerase II as a cellular receptor of various antineoplastic drugs].
    Szmigiero L
    Postepy Biochem; 1988; 34(3):147-52. PubMed ID: 2855749
    [No Abstract]   [Full Text] [Related]  

  • 48. Mechanisms of resistance to topoisomerase inhibitors.
    Chen AY; Liu LF
    Cancer Treat Res; 1994; 73():263-81. PubMed ID: 7710908
    [No Abstract]   [Full Text] [Related]  

  • 49. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.
    Beck WT; Danks MK; Wolverton JS; Chen M; Granzen B; Kim R; Suttle DP
    Adv Pharmacol; 1994; 29B():145-69. PubMed ID: 8996606
    [No Abstract]   [Full Text] [Related]  

  • 50. Topoisomerases and cancer treatment.
    Baguley BC
    N Z Med J; 1991 Nov; 104(924):491-3. PubMed ID: 1660587
    [No Abstract]   [Full Text] [Related]  

  • 51. Mechanisms of resistance to topoisomerases poisons.
    Prost S
    Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Consequences of the resistance to drug-induced topoisomerase II-mediated DNA cleavage.
    Zwelling LA
    Toxicol Lett; 1993 Apr; 67(1-3):231-6. PubMed ID: 8383886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topoisomerases in human leukemia.
    Peereboom D; Charron M; Kaufmann SH
    Adv Pharmacol; 1994; 29B():33-50. PubMed ID: 8996600
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents.
    Wang HK; Morris-Natschke SL; Lee KH
    Med Res Rev; 1997 Jul; 17(4):367-425. PubMed ID: 9211397
    [No Abstract]   [Full Text] [Related]  

  • 55. [Recent progress in the study of drug resistance in cancer cells].
    Liu J; Xu B
    Sheng Li Ke Xue Jin Zhan; 1989 Apr; 20(2):158-60. PubMed ID: 2686016
    [No Abstract]   [Full Text] [Related]  

  • 56. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
    Heck MM; Hittelman WN; Earnshaw WC
    Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1086-90. PubMed ID: 2829215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA topoisomerases as anticancer drug targets.
    Schneider E; Hsiang YH; Liu LF
    Adv Pharmacol; 1990; 21():149-83. PubMed ID: 2176094
    [No Abstract]   [Full Text] [Related]  

  • 58. Topoisomerases II alpha and beta as therapy targets in breast cancer.
    Isaacs RJ; Davies SL; Wells NJ; Harris AL
    Anticancer Drugs; 1995 Apr; 6(2):195-211. PubMed ID: 7795268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Resistance of cancer cells to antineoplastic agents. Can the efficiency of chemotherapy be predicted?].
    Bénard J
    Rev Prat; 1992 Feb; 42(3):318-9. PubMed ID: 1579821
    [No Abstract]   [Full Text] [Related]  

  • 60. Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin.
    Pantazis P; Mendoza JT; DeJesus A; Rubin E; Kufe D; Giovanella BC
    Eur J Haematol; 1994 Sep; 53(3):135-44. PubMed ID: 7925856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.